From: Molecular alterations in key-regulator genes among patients with T4 breast carcinoma
A | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcome | ER | PR | Ki67 | HER2 | Â | Â | Â | ||||||||
 | positives | % | P | positives | % | P | positives | % | P | positives | % | P |  |  |  |
Clinical response | Â | Â | 0.132 | Â | Â | 0.640 | Â | Â | 0.047 | Â | Â | 0.022 | Â | Â | Â |
   Complete response | 3/7 | 43 |  | 3/7 | 43 |  | 5/7 | 71 |  | 8/8 | 100 |  |  |  |  |
Partial response | 16/29 | 55 | Â | 11/29 | 38 | Â | 9/27 | 33 | Â | 27/37 | 73 | Â | Â | Â | Â |
< Partial response | 5/8 | 62 | Â | 2/8 | 25 | Â | 2/8 | 25 | Â | 2/8 | 25 | Â | Â | Â | Â |
Pathological response | Â | Â | 0.469 | Â | Â | 0.235 | Â | Â | 0.042 | Â | Â | 0.095 | Â | Â | Â |
pCR | 4/7 | 57 | Â | 3/7 | 43 | Â | 5/7 | 71 | Â | 7/8 | 87 | Â | Â | Â | Â |
<pCR | 20/37 | 54 | Â | 13/37 | 35 | Â | 11/35 | 31 | Â | 30/45 | 67 | Â | Â | Â | Â |
B | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Outcome | cyclinD1 | h-prune | pERK 1-2 | p53 | survivin | ||||||||||
 | positives | % | P | positives | % | P | positives | % | P | positives | % | P |  |  |  |
Clinical response | Â | Â | 0.457 | Â | Â | 0.824 | Â | Â | 0.032 | Â | Â | 0.391 | Â | Â | 0.089 |
   Complete response | 1/8 | 12 |  | 1/8 | 12 |  | 0/8 | 0 |  | 1/8 | 12 |  | 1/8 | 12 |  |
Partial response | 8/37 | 22 | Â | 5/37 | 14 | Â | 3/37 | 8 | Â | 10/37 | 27 | Â | 15/37 | 41 | Â |
< Partial response | 3/8 | 37 | Â | 2/8 | 25 | Â | 2/8 | 25 | Â | 2/8 | 25 | Â | 5/8 | 62 | Â |
Pathological response | Â | Â | 0.660 | Â | Â | 0.822 | Â | Â | 0.007 | Â | Â | 0.972 | Â | Â | 0.234 |
pCR | 2/8 | 25 | Â | 1/8 | 12 | Â | 0/8 | 0 | Â | 2/8 | 25 | Â | 3/8 | 37 | Â |
<pCR | 10/45 | 22 | Â | 7/45 | 16 | Â | 5/45 | 11 | Â | 11/45 | 24 | Â | 18/45 | 40 | Â |